Roche: shares fall after broker downgrade.

(CercleFinance.com) - Shares of Roche are down 0.
3% at 243.9 Swiss france on Zurich's SMI index on Monday, after Credit Suisse downgraded its rating on the Swiss drugmaker.

The broker downgraded the stock from "outperform" to "neutral," with a target price that it has cut from 300 Swiss francs to 260 Swiss francs.

"We see a marked deterioration in Roche's strategic positioning as biosimilars for Rituxan and Herceptin enter the market adding pricing pressure and marketing burden," Credit Suisse warns in its report.



Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.